Vamikibart Antibody is a research-grade biosimilar monoclonal antibody targeting Hybridoma growth factor. It is a human IgG2-kappa antibody. Reactivity: Human. Supplied as a liquid in 0.01M PBS pH 7.4. Applications: ELISA, flow cytometry, functional assays, in vivo research and Western blot. Endotoxin: < 10 EU/mg. Purity: >95% purity as determined by SDS-PAGE. For research use only.
Interleukin-6 (IL6) is a ~23 kDa protein. Cytokine with a wide variety of biological functions in immunity, tissue regeneration, and metabolism. Binds to IL6R, then the complex associates to the signaling subunit IL6ST/gp130 to trigger the intracellular IL6-signaling pathway (Probable). The interaction with the membrane-bound IL6R and IL6ST stimulates 'classic signaling', whereas the binding of IL6 and soluble IL6R to IL6ST stimulates 'trans-signaling'. Alternatively, 'cluster signaling' occurs when membrane-bound IL6:IL6R complexes on transmitter cells activate IL6ST receptors on neighboring receiver cells (Probable). IL6 is the therapeutic target of tocilizumab (Actemra).
Product Name:
Vamikibart Antibody
SKU:
GXBS02087
Size:
100 µg, 1 mg
Antibody Type:
Monoclonal Antibody
Target:
B-cell stimulatory factor 2
Isotype:
IgG2-kappa
Host Species:
Human
Reactivity:
Human
Applications:
ELISA, FCM, Functional assay, Research in vivo, WB
Synonyms:
2744320-12-3
Recommended Dilutions:
WB: 1:500-1:2000
Purity:
>95% as determined by SDS-PAGE.
Endotoxin Level:
< 10 EU/mg
Formulation:
0.01M PBS pH 7.4.
State of Matter:
Liquid
Regulatory Status:
For research use only. Not suitable for clinical or therapeutic use.
Product Preparation:
Protein A/G purified from cell culture supernatant.
Storage and Handling:
Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
